Cost effectiveness of immune checkpoint inhibitors for treatment of non-small cell lung cancer: A systematic review-Reference-Cited by-同舟云学术

Cost effectiveness of immune checkpoint inhibitors for treatment of non-small cell lung cancer: A systematic review

Published:2020-09-02 Issue:9 Volume:15 Page:e0238536
ISSN:1932-6203
Container-title:PLOS ONE
language:en
Short-container-title:PLoS ONE

Author:

Ding Haiying,Xin Wenxiu,Tong Yinghui,Sun Jiao,Xu Gaoqi,Ye Ziqi,Rao Yuefeng^ORCID

Funder

Natural Science Foundation of Zhejiang Province

Projects of Medical and Health Technology Program in Zhejiang Province

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference48 articles.

1. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries;F Bray;CA: a cancer journal for clinicians,2018

2. Checkpoint inhibitors plus chemotherapy for first-line treatment of advanced non-small cell lung cancer: a systematic review and meta-analysis of randomized controlled trials;AM Tun;Future science OA,2019

3. Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up;D Planchard;Annals of oncology: official journal of the European Society for Medical Oncology,2019

4. Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer;MD Hellmann;The New England journal of medicine,2019

5. Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC;MA Socinski;The New England journal of medicine,2018

Cited by 39 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Discrete Ollivier-Ricci Flow Finds Distinct Subpopulations of Patients Treated with PD-1 Inhibition;2024-08-09

2. The safety and efficacy of binimetinib for lung cancer: a systematic review;BMC Pulmonary Medicine;2024-08-01

3. Cost-effectiveness analysis of the tislelizumab versus docetaxel for advanced or metastatic non-small-cell lung cancer in China;Frontiers in Public Health;2024-07-18

4. Healthcare Resource Utilization and Associated Costs among Patients with Advanced Non-Small-Cell Lung Cancer Receiving Chemotherapy or Immunotherapy in Spain: A Single-Center, Real-World, Exploratory Study;Cancers;2024-05-30

5. Cost determinant of chemotherapy in breast, cervical, and lung cancer in the era of National Health Insurance;PHARM PRACT-GRANADA;2024